The Cooper Companies (COO) Plunges 14.56% as Earnings Miss and Guidance Cut Trigger Massive Selloff

Summary
• The Cooper Companies (COO) experienced a massive intraday plunge, closing at $54.24, a sharp decline of 14.56% from the previous close of $63.48.

• The selloff was directly triggered by a fiscal Q3 revenue miss and a significant cut to Q4 and full-year 2026 guidance.

• Management cited ongoing U.S. channel inventory destocking at its core CooperVision unit as the primary reason for the slowdown.

• The board decided to retain the CooperSurgical unit after bids failed to meet its perceived value, adding to the market's disappointment.

The medical device giant faced a brutal repricing event on Thursday, driven by a confluence of fundamental disappointments and strategic shifts. Despite reporting a slight beat on adjusted EPS, the top-line revenue shortfall and the downward revision of future outlooks spooked investors. The stock traded in a volatile range between a low of $51.01 and a high of $55.27, with turnover surging to over 11.7 million shares as institutional investors rapidly repositioned their portfolios in response to the deteriorating near-term outlook.
Q3 Earnings Miss and Guidance Cut Spark Selloff
The precipitous drop in COO’s share price is fundamentally rooted in the company's fiscal Q3 2026 earnings report and the accompanying guidance revision. Management reported revenue of approximately $1.07 billion, falling short of the $1.10 billion Wall Street consensus, while adjusted EPS of $1.15 narrowly beat estimates. However, the market focused heavily on the forward outlook, which was slashed significantly. Q4 revenue guidance was reduced to $1.057–$1.080 billion, well below the $1.11 billion expected, and Q4 adjusted EPS guidance was cut to $1.05–$1.09, missing the consensus near $1.19. Management attributed the weakness to accelerated U.S. destocking at the CooperVision contact-lens unit, a structural correction expected to persist into the fourth quarter. Furthermore, the strategic review concluded without a sale of the CooperSurgical unit, as bids did not meet the board's valuation threshold, removing a potential catalyst for shareholder value that many had anticipated.

Technical Oversold Signals vs. Bearish Fundamentals: Strategic Options Plays
The technical landscape for COO presents a stark conflict between extreme oversold conditions and a deeply entrenched bearish trend. Traders must navigate this tension carefully, weighing the potential for a technical bounce against the overwhelming fundamental headwinds.

• RSI: 9.87 (Deeply Oversold)

• MACD: -1.64 (Bearish Momentum)

• 50-Day Moving Average: 68.24 (Price Below)

• 200-Day Moving Average: 73.32 (Price Below)

• Bollinger Bands Lower: 65.20 (Price Far Below)

The stock has broken decisively below all key moving averages, including the 50-day and 200-day lines, signaling a shift to a long-term bearish trend. The MACD histogram is deeply negative, confirming strong downward momentum. However, the RSI has plunged to 9.87, entering extreme oversold territory for the first time in days, suggesting a mechanical pressure for a short-term mean reversion or bounce. The stock is trading well below the lower Bollinger Band, historically a zone for potential short-covering rallies. Given the lack of leveraged ETF data, the focus shifts entirely to options strategies that can capitalize on this volatility.

Two options contracts stand out for their balance of leverage, liquidity, and statistical edge:

• COO20261120P55: Put Option, Strike $55, Expiration 2026-11-20. IV Ratio: 31.98%, Leverage: 47.65%, Delta: -0.23, Theta: -0.007, Gamma: 0.04, Turnover: 1,921. This contract offers a moderate delta for directional exposure with a reasonable IV ratio, suitable for hedging against further downside.

• COO20261120C55: Call Option, Strike $55, Expiration 2026-11-20. IV Ratio: 27.25%, Leverage: 21.30%, Delta: 0.51, Theta: -0.035, Gamma: 0.06, Turnover: 41,473. This call option has high liquidity and a gamma above 0.05, making it highly sensitive to price swings, ideal for a speculative bounce play.

The P55 Put offers a cost-effective way to protect against the expected continuation of destocking pressures, while the P55 Call provides a high-gamma vehicle for traders betting on an oversold bounce. For a 5% downside scenario from the current $54.24, the Put option payoff would be calculated based on the projected price drop, offering protection.

If $51.01 support holds, COO20261120C55 offers a high-gamma bounce play; otherwise, COO20261120P55 provides downside protection.

Wait for Stabilization Before Entering COO
The current selloff in COO is driven by specific, manageable, yet painful, operational challenges rather than a systemic failure of the business model. The path to recovery hinges on the successful completion of the CooperVision destocking process and the stabilization of U.S. channel inventory. Investors should remain cautious and avoid catching the falling knife until management provides concrete evidence of growth reacceleration in the fourth quarter. Watch for stabilization in the $51–$52 range and a potential break above the 50-day moving average as early signs of a trend reversal. Meanwhile, keep an eye on sector leader Alcon (ALC), which saw a modest 2.25% decline, to gauge whether the sector is absorbing the shock or amplifying it.